WebPost-mastectomy Radiation Therapy in HER-2 Positive Breast Cancer after Primary Systemic Therapy: Pooled Analysis of TRYPHAENA and NeoSphere Trials thegreenjournal.com 5 WebMay 11, 2016 · In this multicentre, open-label, phase 2 randomised trial in hospitals and medical clinics, treatment-naive adults with locally advanced, inflammatory, or early-stage …
Prise en charge du cancer du sein, avancées et perspectives Breast …
WebApr 10, 2024 · Human Breast Cancer: ... Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating p... Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly wit... De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT... WebDec 10, 2024 · Longer-term follow-up of the global phase III monarchE trial showed an increasing benefit for adding abemaciclib to endocrine therapy in the adjuvant treatment … notfallapotheke weimar
PERJETA® (pertuzumab) Neoadjuvant Outcomes HCP
WebSep 15, 2009 · Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, Eng-Wong J, Kirk S, Cortes J. Long-term efficacy analysis of the randomised, phase II … In this randomized, double-blind, placebo-controlled, phase 3 trial,4,5 we enrolled patients who were at least 18 years of age with locally recurrent, unresectable, or metastatic HER2-positive breast cancer that was centrally confirmed. Eligible patients had a left ventricular ejection fraction (LVEF) of 50% or … See more The CLEOPATRA trial was performed in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of … See more We used the log-rank test to compare overall survival between the two treatment groups, with stratification according to status with respect to adjuvant or neoadjuvant … See more Study drugs were administered intravenously every 3 weeks. Pertuzumab (at a dose of 840 mg) or placebo was given on day 1 of cycle 1, followed by 420 mg on day 1 of each subsequent cycle; trastuzumab … See more Subgroup analyses were performed to ensure robustness of the treatment effect across prespecified categories. All analyses were performed with the use of SAS software, version 8.2 (SAS Institute). See more Webregimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24 (9): 2278-2284. 8. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2024;377(2):122-131. 9. how to set up a square terminal youtube